文献速递淋巴瘤造血干细胞移植与细胞治疗

晚期皮肤T细胞淋巴瘤异基因移植后的总生存:CUTALLO倾向评分匹配对照前瞻性研究

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
PubMed 文献 · J Clin Oncol · 2025-06-13

CUTALLO研究最终分析纳入99例晚期皮肤T细胞淋巴瘤患者,55例(56%)接受异基因造血干细胞移植(HSCT),44例(44%)接受标准治疗。中位随访38.9个月,HSCT组死亡16/55例(29%),非HSCT组死亡22/44例(50%);HSCT组中位总生存(OS)未达到,非HSCT组为51.5个月(95%CI 26.9至51.5),风险比0.40(95%CI 0.20至0.80)。延长随访后,异基因HSCT与显著更长的OS相关。

要点

  • HSCT组死亡16/55例(29%),非HSCT组死亡22/44例(50%)。
  • HSCT组中位OS未达到,非HSCT组为51.5个月(95%CI 26.9至51.5)。
  • HSCT对比标准治疗的风险比为0.40(95%CI 0.20至0.80)。

核心结论

  • 延长随访后,与晚期CTCL标准治疗相比,异基因HSCT与显著更长的OS相关。

研究设计与样本

  • CUTALLO为倾向评分匹配对照前瞻性研究,最终OS分析纳入99例晚期皮肤T细胞淋巴瘤患者。
  • 55例(56%)分配至HSCT组,44例(44%)分配至非HSCT组,中位随访38.9个月。

主要发现

  • HSCT组死亡16/55例(29%),非HSCT组死亡22/44例(50%)。
  • HSCT组中位OS未达到,非HSCT组中位OS为51.5个月(95%CI 26.9至51.5)。
  • HSCT对比非HSCT的风险比为0.40(95%CI 0.20至0.80)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. de Masson A, Beylot-Barry M, Ram-Wolff C, et al. Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study. J Clin Oncol. 2025. PMID: 40513043. doi:10.1200/JCO-25-00183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。